Diag-Nose.io, founded in 2020 and headquartered in Melbourne, Australia, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions.
Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies.
The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.
Company Details
- Employees
- 17
- Founded
- 2020
- Address
- Melbourne, Vic 3207, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.diag-nose.io
- Keywords
- Sydney.
- HQ
- Melbourne, VIC
Diag-Nose.io Questions
Diag-Nose.Io's website is https://www.diag-nose.io
Diag-Nose.Io's LinkedIn profile is https://www.linkedin.com/company/diagnose-io
Diag-Nose.Io has
17 employees.
View email and phone details for 17
employees at Diag-Nose.Io.
Diag-Nose.Io's industry is
Biotechnology Research
Diag-Nose.Io's top competitors are
Qsic,
Supanova Health Pty Ltd,
Harrison.ai,
Next Chapter,
Spoony,
Healthy Mend,
Mygigsters,
Inova Medical,
Medow Health,
Mci Carbon.
Diag-Nose.Io's categories are Biotechnology Research
Diag-Nose.Io's founding year is 2020
